Effect of Lactobacillus Probiotic on Healthy Adults
Overview
Diarrhea is a common side effect of antibiotics; it may prolong hospital stay, increase the risk of other infections, develop into more serious forms of disease, and lead to premature discontinuation of the needed antibiotic. The purpose of this study is to examine the safety and effectiveness of a capsule containing Lactobacillus rhamnosus GG in the prevention of diarrhea associated with antibiotic use.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: April 2012
Interventions
- Biological: Culturelle
- 10^10 Lactobacillus rhamnosus GG per capsule
Arms, Groups and Cohorts
- Experimental: 1
- Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
Clinical Trial Outcome Measures
Primary Measures
- Incidence of diarrhea
- Time Frame: Approximately one month
Participating in This Clinical Trial
Inclusion Criteria
- Participants (male or female inpatients) 18 to 64 years of age who are prescribed antibiotics (single or multiple antibiotics, oral or intravenous) will be recruited from the Fargo VAMC Primary Care Clinic area. – Participants must be able to swallow a capsule. Exclusion Criteria:
Exclusion criteria include diarrhea on admission or within the preceding week
- Reported recurrent diarrhea – Antibiotics in the past four weeks – Significant underlying conditions (e.g. diabetes, structural cardiac defects including valvular defects, history of infective endocarditis, poor cardiac function, immunosuppression, impaired gut integrity, moderate or serious intestinal disorders, malignancies, pancreatitis, indwelling catheters, recent surgery, recent prolonged hospitalization) – Previous bowel surgery – Nutritional restrictions that preclude participation – Hypersensitivity to penicillin G, ampicillin, or erythromycin – Persons who have been prescribed their antibiotic for a duration longer than 3 weeks
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 64 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Fargo VA Medical Center
- Provider of Information About this Clinical Study
- Principal Investigator: Stephanie Borchardt, Tze Shien Lo, MD – Fargo VA Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.